NCT00866658 - GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA) | Biotech Hunter

Enrollment

311

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Lixisenatide (AVE0010)

Self-administered by subcutaneous injections once daily within the hour preceding breakfast.

DRUG

Placebo

Self-administered by subcutaneous injections once daily within the hour preceding breakfast.

DEVICE

Pen auto-injector

DRUG

Sulfonylurea

Sulfonylurea if given, to be continued at a stable dose.

DRUG

Basal Insulin

To be continued at a stable dose.

Trial Locations (4)

Sanofi-Aventis Administrative Office, Tokyo

Sanofi-Aventis Administrative Office, Makati City

Sanofi-Aventis Administrative Office, Seoul

Sanofi-Aventis Administrative Office, Taipei